Published • loading... • Updated
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials - Pharmafile
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two phase 3 trials, cutting exacerbation rates by 29% and 34% among former smokers. Its OBERON and TITANIA trials were replicate, double-blind, placebo-controlled studies involving a total of 2,306 patients with symptomatic COPD and a history of at least two moderate […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
